Skip to content
value.today

Spark Therapeutics, Inc.

Total raised
$73 M
1 round on record
Latest round
$73 M
May 2014
First round on record
May 2014
Today
Private
No later event on record

Funding rounds

1 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Spark Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
May 2014$73 MNo. 1$50 to $250 million

Spark Therapeutics, Inc.: Raise no. 1, May 2014

Investors in this round

28 investors had bought by the notice of Jun 6, 2014: 28 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 3 investors are named for Spark Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$73 M of $73 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Jeffrey D. Marrazzo · Executive Officer, Director
  • Joseph W. La Barge · Executive Officer
  • Anand M. Mehra · Director
  • Arthur M. Dantchik · Director
  • Elliott M. Sigal · Director
  • Lars M. Ekman, M.D. Ph.D. · Director
  • Rogerio M. Vivaldi · Director
  • Steven M. Altschuler · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Jeffrey D. Marrazzo, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Jun 6, 2014. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Spark Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Jun 2014).

    SEC Form D · Jun 2014

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Jun 2014

That is all the official record says: Spark Therapeutics, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

3 named in official filings. Open an investor to see everything it has backed.

Investors in Spark Therapeutics, Inc.
InvestorKindAmountRoundRoleSource
Children's Hospital of Philadelphia FoundationOthernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2015)SEC Form 3
Sofinnova Management VIII, L.L.C.Fund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2015)SEC Form 3
Sofinnova Venture Partners VIII, L.P.Venture capitalnot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2015)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 28 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Spark Therapeutics, Inc.
NameRoleNamed in
Jeffrey D. MarrazzoExecutive officerJun 2014
Joseph W. La BargeExecutive officerJun 2014
Anand M. MehraDirectorJun 2014
Arthur M. DantchikDirectorJun 2014
Elliott M. SigalDirectorJun 2014
Jeffrey D. MarrazzoDirectorJun 2014
Lars M. Ekman, M.D. Ph.D.DirectorJun 2014
Rogerio M. VivaldiDirectorJun 2014
Steven M. AltschulerDirectorJun 2014